ContraceptionIMPROVE-itNCT05521646
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
A study testing Quality Improvement Collaborative in people with Contraception and Immigrant, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
Immigrant women in Europe has reported lower use of effective contraception, higher risks of multiple births, and unintended pregnancies compared to native-born women. There is no evidence about this from a Swedish context nor about postpartum contraception. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Contraception, Immigrant, Post Partum
- What is being tested?
- Quality Improvement Collaborative
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,000 participants
- Where
- 1 siteSweden
- Study dates
- 5 Sep 2022to Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women coming for postpartum visit within 16 weeks post birth (live birth)
Who cannot join
- Women who do not anticipate becoming sexually active with a male partner within six months.
Trial locations and contacts
1 site in 1 country.
Helena Kilander, PhD contact
Sweden1 site, 1 recruiting
- Recruiting
Karolinska Inst.
Stockholm, 17177
Elin Larsson, PhD, +46702735609, elin.larsson@ki.se
About this study
Official title: Promoting Equitable Reproductive Health: Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
Immigrant women in Europe has reported lower use of effective contraception, higher risks of multiple births, and unintended pregnancies compared to native-born women. There is no evidence about this from a Swedish context nor about postpartum contraception.
The purpose of this project is to promote equity in sexual and reproductive health (SRH) in Sweden by improving the quality of postpartum contraceptive counselling for and with immigrant women.
The Swedish Pregnancy Registry (SPR) will be used to determine if there are any differences in birth spacing and associated complications when comparing immigrant and Swedish-born women. Registration of contraceptive methods in the SPR will be introduced. The IMPROVE-it project will increase the understanding of challenges to contraceptive services postpartum, and how to overcome these.
Read the detailed description
This cRCT will be conducted at MHCs in the regions of Jönköping, Västra Götaland and Stockholm. The unit of randomization will be the clinics. The Swedish pregnancy Register (SPR) will be used to collect data on the women's choice of postpartum contraceptive method, and the proportion of women choosing an effective method will be compared between control and intervention clinics. A survey will be completed for both groups at the postpartum visit at MHCs within 16 weeks postpartum to evaluate the choice of contraceptive method and the counselling received, as well as six and 12 months after the visit to determine ongoing contraceptive use and satisfaction with the method. Furthermore, the follow up at six and 12 months will identify any unintended or planned pregnancy, abortion, or miscarriage that has happened since the postpartum visit.
Inclusion criteria: Women coming for postpartum visit within 16 weeks post birth (live birth). Exclusion criteria: Women below 18 years or having had a still birth. The intervention clinics will register women's choice of contraception during the postpartum MHC visit and participate in Quality Improvement Collaboratives (QIC) for 12 months. The control clinics will provide routine care, register women's choice of contraception in the SPR. Recruitment: Both type of clinics will register women's choice of contraception in the SPR at the postpartum visit within 16 weeks after giving birth and ask women for consent to participate in the study, i.e. respond to a self-administered questionnaire during the visit and be contacted for follow-up. Main outcome: Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women, as registered in the SPR at the postpartum visit within 16 weeks after giving birth.
Secondary outcomes:
At enrolment:
- Women's satisfaction with the contraceptive counselling At six and 12 months after the postpartum visit:
- Use of contraception (and type)
- Satisfaction with the contraceptive method
- Experiences of unintended pregnancy, abortion, miscarriages since the postpartum visit
- Experiences of planned pregnancy since the postpartum visit
The Intervention: A QIC Initiative will be designed based on insights from the pilot study. Within the QIC, the MHCs will test evidence-based changes for contraceptive services during action periods and evaluate these during four learning seminars. Examples of evidence-based changes include using a visual aid to show contraceptive effectiveness translated to the most common languages or a person-centered counselling method based on approaches in MI and RPL. Four learning seminars will be carried out; inbetween them, there will be action periods when the midwives will test the changes made to contraceptive services in their MHC practice. Content of the learning seminars: Quality improvement methods-training; Updates on evidence-based contraceptive counselling; Feedback of data from the SPR on women's choice of contraception; Planning and evaluating tests of evidence-based changes at the MHC; Codeveloping contraceptive services in collaboration between midwives, researchers, and representatives from the target population. Part of the QIC is to continuously give data feedback to the clinics involved on women's choice of contraception. Data collection: The SPR will be used to collect and retrieve data for the primary outcome and background characteristics; a questionnaire will be used to collect data on the secondary outcome 1-2. At six and 12 months, a follow up questionnaire will be used to collect the secondary outcomes 2-5. This will be administered by SMS, email or mail. Three reminders will be sent.
Sample size and statistical power: The pilot study saw a 17% increase in the proportion of immigrant women choosing SARC/LARC. From this increase, we anticipate that at least the same share of the intervention group will be choosing SARC/LARC. Because of the cluster design, an intraclass correlation (ICC) factor affects and increases the sample size needed. The sample size was calculated to show a difference in proportions of participants choosing SARC/LARC in a two-group comparison between intervention and control groups. An assumed ICC of 0.05 was used, equivalent to the ICC observed in a similar study. To show the anticipated 15% difference in SARC/LARC choice with a 90% power at an α=0.05 (i.e. the probability of falsely rejecting a true null hypothesis), we need to include 14-15 clinics in each of the control and intervention groups, each contributing with an average of 100 participants. We will include a total of 29 clinics to allow for dropouts of clinics. The sample size calculations were performed by using the package clusterPower version 0.6.111 in R version 3.6.1. No power calculation was performed for secondary outcomes. Analysis: The analysis population will consist of all women in the cRCT. The primary analysis for the main outcome will be undertaken on an 'intention-to-treat' basis, i.e. all women with a recorded outcome will be included in the analysis and analyzed according to the group to which they were allocated, i.e. the proportion of women choosing SARC/LARC between our two randomized groups. We will further estimate the effect of the QIC using logistic regression analysis. Odds Ratios with 95% confidence intervals will be generated. A multivariate analysis will be performed to control for age, sociodemographic characteristics, and reproductive history.
- Conditions
- Contraception, Immigrant, Post Partum
- Being tested
- Quality Improvement Collaborative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quality Improvement CollaborativeOther
Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | QiC implemented Receives: Other: Quality Improvement Collaborative |
| Control | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women.
Data collection as registered in the Swedish pregnancy register at the postpartum visit within 16 weeks after giving birth.
Measured: 12 months
Secondary outcomes (5)
Womens satisfaction with the contraceptive counselling provided at the postpartum visit
Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone).
Measured: 12 months
Participants´ use of contraception (and type) at six and 12 months follow-up
A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.
Measured: 18-24 months
Participants´ satisfaction with the contraceptive method at six and 12 months follow-up
A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.
Measured: 18-24 months
Participants´ experiences of unintended pregnancy, abortion, miscarriages since the postpartum visit, at six and 12 months follow-up
A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.
Measured: 18-24 months
Participants´ experiences of planned pregnancy since the postpartum visit, at six and 12 months follow-up
A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.
Measured: 18-24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2022
- Study start5 Sep 2022
- Primary completionSep 2023 (estimated)
- Study completionSep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ContraceptionStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- cluster randomized controlled trial
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- The Swedish Research Council, Forte
- Responsible party
- Principal investigator, Elin Larsson, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05521646
- Sponsor's protocol ID
- Dnr 2021-05962-01
- Acronym
- IMPROVE-it
- Status last verified
- Oct 2022
- First submitted
- 25 Aug 2022
- Last updated
- 10 Oct 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kilander H, Sorcher R, Berglundh S, Petersson K, Wangborg A, Danielsson KG, Iwarsson KE, Branden G, Thor J, Larsson EC. IMplementing best practice post-partum contraceptive services through a quality imPROVEment initiative for and with immigrant women in Sweden (IMPROVE it): a protocol for a cluster randomised control trial with a process evaluation. BMC Public Health. 2023 May 3;23(1):806. doi: 10.1186/s12889-023-15776-8.
PubMed 37138268
Study at a glance
From the registry record, last updated by the sponsor on 10 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Promoting Equitable Reproductive Health: Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
- ClinicalTrials.gov ID
- NCT05521646
- Acronym / sponsor ID
- IMPROVE-it / Dnr 2021-05962-01
- Conditions
- Contraception, Immigrant, Post Partum
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- The Swedish Research Council, Forte
- Study start
- 5 Sep 2022 (actual)
- Primary completion
- Sep 2023 (estimated)
- Study completion
- Sep 2025 (estimated)
- First posted
- 30 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Immigrant women in Europe has reported lower use of effective contraception, higher risks of multiple births, and unintended pregnancies compared to native-born women. There is no evidence about this from a Swedish context nor about postpartum contraception.
The purpose of this project is to promote equity in sexual and reproductive health (SRH) in Sweden by improving the quality of postpartum contraceptive counselling for and with immigrant women.
The Swedish Pregnancy Registry (SPR) will be used to determine if there are any differences in birth spacing and associated complications when comparing immigrant and Swedish-born women. Registration of contraceptive methods in the SPR will be introduced. The IMPROVE-it project will increase the understanding of challenges to contraceptive services postpartum, and how to overcome these.
Detailed description
This cRCT will be conducted at MHCs in the regions of Jönköping, Västra Götaland and Stockholm. The unit of randomization will be the clinics. The Swedish pregnancy Register (SPR) will be used to collect data on the women's choice of postpartum contraceptive method, and the proportion of women choosing an effective method will be compared between control and intervention clinics. A survey will be completed for both groups at the postpartum visit at MHCs within 16 weeks postpartum to evaluate the choice of contraceptive method and the counselling received, as well as six and 12 months after the visit to determine ongoing contraceptive use and satisfaction with the method. Furthermore, the follow up at six and 12 months will identify any unintended or planned pregnancy, abortion, or miscarriage that has happened since the postpartum visit.
Inclusion criteria: Women coming for postpartum visit within 16 weeks post birth (live birth). Exclusion criteria: Women below 18 years or having had a still birth. The intervention clinics will register women's choice of contraception during the postpartum MHC visit and participate in Quality Improvement Collaboratives (QIC) for 12 months. The control clinics will provide routine care, register women's choice of contraception in the SPR. Recruitment: Both type of clinics will register women's choice of contraception in the SPR at the postpartum visit within 16 weeks after giving birth and ask women for consent to participate in the study, i.e. respond to a self-administered questionnaire during the visit and be contacted for follow-up. Main outcome: Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women, as registered in the SPR at the postpartum visit within 16 weeks after giving birth.
Secondary outcomes:
At enrolment:
- Women's satisfaction with the contraceptive counselling At six and 12 months after the postpartum visit:
- Use of contraception (and type)
- Satisfaction with the contraceptive method
- Experiences of unintended pregnancy, abortion, miscarriages since the postpartum visit
- Experiences of planned pregnancy since the postpartum visit
The Intervention: A QIC Initiative will be designed based on insights from the pilot study. Within the QIC, the MHCs will test evidence-based changes for contraceptive services during action periods and evaluate these during four learning seminars. Examples of evidence-based changes include using a visual aid to show contraceptive effectiveness translated to the most common languages or a person-centered counselling method based on approaches in MI and RPL. Four learning seminars will be carried out; inbetween them, there will be action periods when the midwives will test the changes made to contraceptive services in their MHC practice. Content of the learning seminars: Quality improvement methods-training; Updates on evidence-based contraceptive counselling; Feedback of data from the SPR on women's choice of contraception; Planning and evaluating tests of evidence-based changes at the MHC; Codeveloping contraceptive services in collaboration between midwives, researchers, and representatives from the target population. Part of the QIC is to continuously give data feedback to the clinics involved on women's choice of contraception. Data collection: The SPR will be used to collect and retrieve data for the primary outcome and background characteristics; a questionnaire will be used to collect data on the secondary outcome 1-2. At six and 12 months, a follow up questionnaire will be used to collect the secondary outcomes 2-5. This will be administered by SMS, email or mail. Three reminders will be sent.
Sample size and statistical power: The pilot study saw a 17% increase in the proportion of immigrant women choosing SARC/LARC. From this increase, we anticipate that at least the same share of the intervention group will be choosing SARC/LARC. Because of the cluster design, an intraclass correlation (ICC) factor affects and increases the sample size needed. The sample size was calculated to show a difference in proportions of participants choosing SARC/LARC in a two-group comparison between intervention and control groups. An assumed ICC of 0.05 was used, equivalent to the ICC observed in a similar study. To show the anticipated 15% difference in SARC/LARC choice with a 90% power at an α=0.05 (i.e. the probability of falsely rejecting a true null hypothesis), we need to include 14-15 clinics in each of the control and intervention groups, each contributing with an average of 100 participants. We will include a total of 29 clinics to allow for dropouts of clinics. The sample size calculations were performed by using the package clusterPower version 0.6.111 in R version 3.6.1. No power calculation was performed for secondary outcomes. Analysis: The analysis population will consist of all women in the cRCT. The primary analysis for the main outcome will be undertaken on an 'intention-to-treat' basis, i.e. all women with a recorded outcome will be included in the analysis and analyzed according to the group to which they were allocated, i.e. the proportion of women choosing SARC/LARC between our two randomized groups. We will further estimate the effect of the QIC using logistic regression analysis. Odds Ratios with 95% confidence intervals will be generated. A multivariate analysis will be performed to control for age, sociodemographic characteristics, and reproductive history.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- cluster randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Other: Quality Improvement CollaborativeQiC implemented |
| Control | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Women coming for postpartum visit within 16 weeks post birth (live birth)
Key exclusion criteria (1 listed)
- Women who do not anticipate becoming sexually active with a male partner within six months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quality Improvement CollaborativeExplore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method | Other | Intervention |
Primary outcome
Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women.
Time frame: 12 months
Data collection as registered in the Swedish pregnancy register at the postpartum visit within 16 weeks after giving birth.
5 secondary outcomes
Womens satisfaction with the contraceptive counselling provided at the postpartum visit
Time frame: 12 months
Participants´ use of contraception (and type) at six and 12 months follow-up
Time frame: 18-24 months
Participants´ satisfaction with the contraceptive method at six and 12 months follow-up
Time frame: 18-24 months
Participants´ experiences of unintended pregnancy, abortion, miscarriages since the postpartum visit, at six and 12 months follow-up
Time frame: 18-24 months
Participants´ experiences of planned pregnancy since the postpartum visit, at six and 12 months follow-up
Time frame: 18-24 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Oct 2022.
- Derived from this study: PubMed 37138268Kilander H, Sorcher R, Berglundh S, Petersson K, Wangborg A, Danielsson KG, Iwarsson KE, Branden G, Thor J, Larsson EC. IMplementing best practice post-partum contraceptive services through a quality imPROVEment initiative for and with immigrant women in Sweden (IMPROVE it): a protocol for a cluster randomised control trial with a process evaluation. BMC Public Health. 2023 May 3;23(1):806. doi: 10.1186/s12889-023-15776-8.
Related trials for Contraception
Recruiting
Impact of Self-Care Family Planning Services on Health and Development in South Sudan (Family Planning Impact Lab)
Contraceptive Behavior, Self Administration
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
Contraception
Not yet recruitingPhase 3
Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)
Contraception
Not yet recruiting
Safety of a Contraceptive Copper Vaginal Ring
Contraception, Birth Control
Recruiting
"Vasectomy: Right for Me?" Decision Support Tool
Vasectomy, Contraception
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Helena Kilander, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Quality Improvement Collaborative in people with Contraception and Immigrant, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Elin Larsson, PhD (+46702735609, elin.larsson@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05521646, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2022; AzTrials last refreshed its copy on 29 Oct 2026.